Your Article Summary
Safety, therapeutic effectiveness, and cost of parenteral iron therapy
International Journal of Hematology, 06/10/09
Asma S et al. - Although the cost of intravenous iron sucrose therapy may seem high, a lack of adherence to therapy and side effects including gastrointestinal irritation during oral iron therapy were not experienced during intravenous therapy.
Related Articles
A New Era in Iron Chelation Therapy: The Design of Optimal, Individually Adjusted Iron Chelation Therapies for the Complete Removal of Iron Overload in Thalassemia and other Chronically Transfused Patients
Hemoglobin, 10/23/09
Relevance Score: 71%
Can intravenous iron therapy meet the unmet needs created by the new restrictions on erythropoietic stimulating agents
Transfusion, 11/23/09
Relevance Score: 70%
Update on the use of deferasirox in the management of iron overload
Therapeutics and Clinical Risk Management, 11/05/09
Relevance Score: 68%
Understanding Iron Overload:Screening, Monitoring, and Caring for Patients With Transfusion-Dependent Anemias
Clinical Journal of Oncology Nursing, 10/06/09
Relevance Score: 68%
Iron-Refractory Iron Deficiency Anemia
Seminars in Hematology, 10/05/09
Relevance Score: 68%
Today in Anemia/Polycythemia...keeping you current
Receive free subspecialty "5-minute updates" via email
Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia
Journal of Thrombosis and Haemostasis, 12/19/09
Hematogones are markedly reduced in pediatric acquired aplastic anemia: multiparametric flow cytometric analysis
Leukemia and Lymphoma, 12/17/09
Red Blood Cell Distribution Width and Risk of Cardiovascular Events and Mortality in a Community Cohort in Taiwan
American Journal of Epidemiology, 12/17/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase
Journal of Clinical Oncology, 12/20/09
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
Journal of Clinical Oncology, 12/20/09
Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia
Journal of Clinical Oncology, 12/20/09

See Latest Articles